Urinary α1 microglobulin level is useful for selecting sodium‐glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes-Reference-Cited by-同舟云学术

Urinary α1 microglobulin level is useful for selecting sodium‐glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes

Published:2023-06-29 Issue:10 Volume:25 Page:3071-3075
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Koshizaka Masaya¹²³^ORCID,Ishibashi Ryoichi²⁴^ORCID,Ishikawa Ko¹²,Shoji Mayumi¹²,Ide Kana¹²,Ide Shintaro¹²,Kato Hisaya¹²,Teramoto Naoya¹²,Terayama Ryo¹²,Maezawa Yoshiro¹²^ORCID,Yokote Koutaro¹²^ORCID,

Affiliation:

1. Department of Medicine, Division of Diabetes, Metabolism and Endocrinology Chiba University Hospital Chiba Japan

2. Department of Endocrinology, Hematology and Gerontology Chiba University Graduate School of Medicine Chiba Japan

3. Center for Preventive Medical Sciences Chiba University Chiba Japan

4. Department of Medicine, Division of Diabetes, Endocrinology and Metabolism Kimitsu Chuo Hospital Chiba Japan

Funder

Astellas Pharma

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference16 articles.

1. A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes

2. Reduction of Visceral Fat Is Associated With Decrease in the Number of Metabolic Risk Factors in Japanese Men

3. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

4. Beneficial effects of metformin on energy metabolism and visceral fat volume through a possible mechanism of fatty acid oxidation in human subjects and rats

5. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)